1,976 results on '"Mok, Tony"'
Search Results
252. Low-dose selenite synergizes with KRAS inhibitor as a dual apoptotic and ferroptotic agent in lung adenocarcinoma.
253. Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
254. Heterogeneity of tumor immune microenvironment and real-world analysis of immunotherapy efficacy in lung adenosquamous carcinoma.
255. Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
256. Moderate coffee consumption reduces the risk of hepatocellular carcinoma in hepatitis B chronic carriers: a case—control study
257. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer
258. Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials
259. Piloting electronic self report symptom assessment – Cancer (ESRA-C) in Hong Kong: A mixed method approach
260. Lung cancer in never smokers: Change of a mindset in the molecular era
261. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
262. Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
263. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
264. Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
265. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance
266. Single-Port Video-Assisted Thoracoscopic Major Lung Resections: Experience with 150 Consecutive Cases
267. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer: The ASPIRATION Study
268. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
269. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
270. Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia.
271. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
272. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non–Small Cell Lung Cancer.
273. Efficacy and Safety of Erlotinib in 1242 East/South-East Asian Patients with Advanced Non-small Cell Lung Cancer
274. Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors
275. Genetic Evolution of Epidermal Growth Factor Receptor in Adenocarcinoma With a Bronchioloalveolar Carcinoma Component
276. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
277. Population-based differences in treatment outcome following anticancer drug therapies
278. Thromboxane synthase suppression induces lung cancer cell apoptosis via inhibiting NF-κB
279. Local ablative radiotherapy on oligo‐progression while continued on epidermal growth factor receptor tyrosine kinase inhibitors in advanced non–small cell lung cancer patients: A longer cohort
280. Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas: Erratum
281. Abstract LBA035: Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer: CANOPY-N Trial
282. 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer
283. 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status
284. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
285. Inhibition of thromboxane synthase induces lung cancer cell death via increasing the nuclear p27
286. Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis
287. Antineoplastic effects of 15(S)-hydroxyeicosatetraenoic acid and 13-S-hydroxyoctadecadienoic acid in non–small cell lung cancer
288. Novel targeted agents for the treatment of lung cancer in China
289. First-Line Crizotinib in ALK-Positive Lung Cancer
290. First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009
291. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview
292. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
293. Strategy on Patients with EGFR Mutation
294. Supplement to: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
295. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
296. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer
297. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
298. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
299. Management of Hepatocellular Carcinoma: Beyond Sorafenib
300. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.